To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile BRAF V600E
Therapy Panitumumab
Indication/Tumor Type colorectal cancer
Response Type resistant

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
BRAF V600E colorectal cancer resistant Panitumumab Clinical Study - Meta-analysis Actionable In a meta-analysis, the addition of Erbitux (cetuximab) or Vectibix (panitumumab) to standard of care treatment with chemotherapy did not result in improved progression-free survival (HR=0.88; 95% CI, 0.67-1.14; p=0.33), overall survival (HR=0.91; 95% CI, 0.62-1.34; p=0.63), or objective response rate (relative risk=1.31; 95% CI, 0.83-2.08; p=0.25) in patients with advanced colorectal cancer harboring BRAF V600E (PMID: 25673558). 25673558
BRAF V600E colorectal cancer resistant Panitumumab Clinical Study Actionable In a retrospective analysis, metastatic colorectal cancer patients harboring BRAF V600E demonstrated shorter progression-free survival (p=0.0107) and overall survival (p<0.0001) compared to patients with wild-type BRAF following Vectibix (panitumumab) or Erbitux (cetuximab) therapy with or without chemotherapy, and in a preclinical study, colorectal cancer cell lines harboring BRAF V600E were resistant to Vectibix (panitumumab) in culture (PMID: 19001320). 19001320
BRAF V600E colorectal cancer resistant Panitumumab Guideline Actionable Vectibix (panitumumab), as a monotherapy, is not indicated for use in metastatic colorectal cancer patients with BRAF V600E (PMID: 36307056; ESMO.org). 36307056 detail...
PubMed Id Reference Title Details
ESMO Clinical Practice Guidelines Full reference...
(36307056) Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Full reference...
(25673558) Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Full reference...
(19001320) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. Full reference...